3-Furoic acid (furan-3-carboxylic acid, CAS 488-93-7, molecular formula C5H4O3, relative molecular mass 112.08) is released for pharmaceutical formulation development as a non-compendial active pharmaceutical ingredient under ICH Q7 GMP conditions. The compound is a weak monoprotic carboxylic acid with a reported melting point of 121–123 °C and a pKa in the region of 4.0, positioning ionization and dissolution behaviour in the pH range between gastric fluid and intestinal fluid. Because clinical indication and daily dose are buyer-defined, the following formulation ratios are expressed as mass fractions of the finished pharmaceutical unit rather than absolute therapeutic amounts. For markets where a dedicated USP or Ph. Eur. monograph is not available, the vendor certificate of analysis is aligned with ICH Q3A(R2) for unspecified impurity thresholds of 0.05% when the maximum daily intake is ≤2 g/day, ICH Q3C(R8) for residual solvents, and ICH Q3D(R2) for elemental impurities. Solid-dose release testing references USP <905> uniformity of dosage units and USP <711> dissolution; parenteral release references USP <1>, USP <71>, USP <85>, and USP <788>. The following scenarios cover tablet, capsule, granule, and injectable processing routes for this API.

Under direct-compression conditions, 3-furoic acid is incorporated into an immediate-release tablet matrix only after particle size distribution and powder-flow characterization; when the milled crystals show a Carr index above 30%, dry granulation is inserted ahead of compression. A standard direct-compression formula places 3-furoic acid at 10–25% w/w of the core mass, microcrystalline cellulose and spray-dried lactose at 60–80% w/w, croscarmellose sodium at 2–5% w/w, colloidal silicon dioxide at 0.5–1.0% w/w, and magnesium stearate at 0.5–1.0% w/w. Processing on a 16-station rotary tablet press with 10 mm flat-faced bevel-edge tooling typically requires main compression force between 6 kN and 12 kN; cores are adjusted to hardness 60–100 N and tested by USP <711> apparatus 2 paddle dissolution at 50 rpm in 900 mL of pH 6.8 phosphate buffer. Compliance is governed by 21 CFR 210/211 finished pharmaceutical cGMP, with tablet weight variation according to Ph. Eur. 2.9.5 and blend uniformity according to USP <905>. Production-scale experience shows that when relative humidity exceeds 55%, the free acid form can generate punch-face filming on standard tool steel; the corrective action is use of stainless steel 316L tooling and pre-drying at 40–45 °C until loss-on-drying is below 0.5%. Terminal product type: immediate-release film-coated tablets, round biconvex cores of 200–400 mg target weight, packaged in HDPE bottles with desiccant to limit moisture ingress.

When Does Roller Compaction Become Mandatory Before Capsule Filling?

Encapsulation of 3-furoic acid on a high-speed capsule filler is permitted only when the powder blend exhibits a flow function coefficient above 4 and a minimum orifice diameter below 10 mm in USP <1174> powder-flow testing; otherwise, dry granulation by roller compaction is inserted before filling. The formulation addition ratio for hard gelatin capsules size 1–3 typically places the API at 15–40% w/w, anhydrous lactose or mannitol at 45–75% w/w, pregelatinised starch at 5–10% w/w, sodium stearyl fumarate at 0.5–1.5% w/w, and colloidal silicon dioxide at 0.5–1.0% w/w. Roller compaction is performed on a Gerteis Mini-Pactor or Alexanderwerk WP 120 with roll pressure 2–6 kN/cm, roller gap 1.5–3.0 mm, and ribbon density controlled to 0.85–1.05 g/cm³. The milled granulate is sieved to a D50 between 150 µm and 300 µm, and the fraction of fines below 15% of total mass is monitored to prevent segregation in the capsule filler hopper. Industry compliance is anchored by ICH Q3C(R8) for residual solvents and USP <616> for bulk and tapped density; a Hausner ratio above 1.35 before compaction is a production-scale indicator that the blend will stratify on the dosator or tamping-pin capsule machine. Terminal product type: hard gelatin capsule, sizes 1–3, with lock-ring closure and fill weight 250–500 mg controlled within ±5% of target; shell compatibility is evaluated under 40 °C/75% RH stability conditions for embrittlement and crosslinking risk.

Granule Wet Granulation Endpoint Parameters and Loss-on-Drying Control

In high-shear wet granulation for oral sachet dosing or reconstitution, 3-furoic acid is formulated at 20–50% w/w of the dry granule mass, with povidone K30 binder at 5–10% w/w, lactose monohydrate filler at 30–60% w/w, sodium starch glycolate disintegrant at 2–4% w/w, and hypromellose 5 cP as optional binder or top-spray coating polymer. The downstream process uses a 65 L high-shear granulator with impeller speed 200–350 rpm and chopper speed 1500–3000 rpm; purified water is metered at 0.2–0.5 L/min. Water addition rates above 0.5 L/min can create localized over-wetting, torque spikes, and oversized agglomerates above 850 µm. The endpoint is defined by an impeller torque rise of 15–25% above dry-mix baseline and formation of granules with D50 150–350 µm; wet mass is transferred to a fluid-bed dryer with inlet air at 50–60 °C and dried until loss-on-drying reaches 1.5–2.5%. Oversized granules above 850 µm are size-reduced through a cone mill fitted with a 610 µm screen. Compliance is established through Ph. Eur. 2.9.12 sieve analysis, USP <786> analytical sieving, and Ph. Eur. 2.9.5 mass uniformity for single-dose granules. Terminal product type: coated granule for sachet or reconstituted oral suspension, filled at 100–1000 mg unit doses into triple-laminated aluminium–polyethylene sachets with moisture vapour transmission rate below 0.5 g/m²/day.

Injectable freeze-dried dosage forms require pre-lyophilisation solution development because the free carboxylic acid can convert to the sodium salt during pH adjustment. A pre-lyophilisation solution is compounded in Water for Injection at 0.5–5.0 mg/mL expressed as free acid equivalent; when the free acid is used, stoichiometric neutralisation with 1 M NaOH to a target pH of 5.5–7.0 is performed at 15–25 °C. The solution contains mannitol or glycine as bulking agent at 2–5% w/v, and a phosphate or citrate buffer at 10–50 mM. Aseptic filtration is performed through a 0.22 µm PVDF or polyethersulfone membrane according to ISO 13408-1:2008, and the filtrate is filled into 10 mL Type I borosilicate glass vials with chlorobutyl rubber stoppers under EU GMP Grade A conditions. Lyophilisation uses shelf freezing at -40 °C for 2–4 h, primary drying at -25 °C to -15 °C with chamber pressure 50–150 mTorr for 20–40 h, and secondary drying at 25–35 °C for 4–8 h; endpoint is confirmed when the Pirani gauge and capacitance manometer pressure differential drops below 5 mTorr. During primary drying, product temperature is maintained at least 2 °C below the freeze-concentrate collapse temperature determined by freeze-dry microscopy; exceeding this boundary produces cake collapse and poor reconstitution. Published lyophilisation cycle data for 3-furoic acid specifically is limited; cycle parameters are therefore justified by buyer-specific forced-degradation and thermal characterization rather than by a compendial cycle. Sterility testing follows USP <71> and Ph. Eur. 2.6.1, bacterial endotoxins USP <85> and Ph. Eur. 2.6.14, particulate matter USP <788> method 1 light obscuration, and elemental impurities ICH Q3D(R2). Terminal product type: lyophilised powder for injection in a 10 mL Type I glass vial, reconstituted with 2–5 mL of WFI or 0.9% sodium chloride injection to a clear solution at pH 5.5–7.0 within 60 seconds.

If Aseptic Filtration Is Selected for Ready-to-Use Injectable Solution

For ready-to-use injectable solutions, aseptic filtration is selected when forced-degradation data show that a terminal steam sterilisation cycle of 121 °C for 15 min produces degradation products above ICH Q3B(R2) qualification thresholds. The formulation addition ratio is typically 0.5–2.0% w/v 3-furoic acid, equivalent to 5–20 mg/mL, with phosphate or citrate buffer at 10–50 mM, sodium chloride as tonicity agent at 7.5–9.0 mg/mL, and final pH adjusted to 5.5–6.5 using 1 M HCl or 1 M NaOH. Compounding is performed in a 316L stainless steel vessel under nitrogen overlay if oxygen-sensitive degradation is identified, followed by pre-filtration through a 0.45 µm membrane and sterile filtration through a 0.22 µm membrane. The solution is filled into depyrogenated containers under ISO 14644-1 Class 5 / EU GMP Grade A; terminal sterilisation is introduced only when forced-degradation and container-closure interaction data support a shelf-life acceptance criterion without excessive impurities. Compliance is driven by 21 CFR 210/211, USP <1> Injections, USP <790> visible particulates, and ICH Q3C(R8) for residual solvents from component processing. Terminal product type: ready-to-use solution in 2 mL, 5 mL, or 10 mL Type I glass ampoules or vials, with release tests for pH, endotoxin, sterility, particulate matter, and assay.

Pre-filled syringe presentations introduce a separate stability boundary because the carboxylate group can interact with silicone oil lubricant on glass barrels and with elastomer components. In a 0.5–1.0 mL pre-filled syringe, 3-furoic acid content is set at 0.5–2.0 mg/mL, citrate buffer strength at 10–25 mM, sodium chloride at 7.5–9.0 mg/mL, and target osmolality at 280–320 mOsm/kg. The glass barrel is spray-siliconised with medical-grade polydimethylsiloxane at 0.2–0.4 mg/cm²; after aseptic filling and stoppering, subvisible silicone droplets of ≥10 µm are monitored by light obscuration and flow imaging over 12 weeks at 25 °C/60% RH. The manufacturing process uses a 0.22 µm sterile filter, EU GMP Grade A filling, and residual headspace oxygen control below 5% to limit oxidative degradation. Applicable standards include ISO 11040-4 for glass barrels, USP <660> for glass containers, USP <381> for elastomeric closures, and USP <788> for particulate matter. Terminal product type: single-use pre-filled syringe with Luer lock or Luer slip closure, nominal fill volume 0.5 mL or 1.0 mL, released only after visual inspection and container-closure integrity testing.